Cecilia Vicuna Keady
Family Medicine · Charlestown, NHNPI 1558334656
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,639 of the $12,798 with a category attached, or 83.1%. It is spread thinly across 46 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $5,120 and has fallen 58.9% since, to $2,106 in 2025. Among family medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 558 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Boehringer Ingelheim$2K
- AstraZeneca$2K
- Merz North America, Inc.$793
- Pfizer$729
- Lilly USA, LLC$679
- plus $5K from 40 others
What the payments were for
- Consulting fees$1,56812%
- Speaking & faculty fees$3823%
- Food & beverage$10,63983%
- Education$2102%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STIOLTO RESPIMAT$1,568
- XEOMIN$674
How this compares
$12,798 in reported general payments places this provider in the 95th percentile of 397 family medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $167,475 |
| MounjaroTirzepatide | 125 | $165,061 |
| EliquisApixaban | 73 | $75,613 |
| FarxigaDapagliflozin Propanediol | 54 | $70,402 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $41,510 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $20,758 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $14,462 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,078 |
| XareltoRivaroxaban | 12 | $11,036 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $8,904 |
| JanuviaSitagliptin Phosphate | 11 | $8,328 |
| Fenofibrate | 13 | $4,078 |
| Doxepin Hcl | 12 | $3,973 |
| Duloxetine Hcl | 106 | $3,613 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $3,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $665 | $167,475125 claims |
| Lilly USA, LLCMounjaro | $679 | $165,061125 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,521 | $82,48073 claims |
| PfizerEliquis | $729 | $75,61373 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $404 | $55,97269 claims |
| Johnson & JohnsonXarelto | $61 | $11,03612 claims |
| MerckJanuvia | $117 | $8,32811 claims |
| AbbVieSynthroid | $2,247 | $3,09648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 397 family medicine providers in New Hampshire.
Other family medicine in Charlestown
- Mark BallentynePortsmouth$135K
- M LauterPortsmouth$21K
- Brian SponsellerNorth Conway$15K
- Keenan Al-HojerryPortsmouth$11K
- Peter LoeserConcord$10K
- Robyn StewartDerry$8K
- Robert KellyExeter$8K
- Dennis BadmanSanbornville$7K
- Ajay KoshyBedford$6K
- Douglas DrefferDerry$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.